David Lebowitz
Stock Analyst at Citigroup
(2.01)
# 1,509
Out of 4,413 analysts
66
Total ratings
36.67%
Success rate
-6.99%
Average return
Main Sectors:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | $382 | $204.02 | +87.24% | 1 | Mar 6, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $47 → $39 | $24.38 | +59.97% | 6 | Mar 1, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $11 → $13 | $6.50 | +100.00% | 2 | Feb 26, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $46 | $25.62 | +79.55% | 2 | Feb 23, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $54 → $65 | $91.34 | -28.84% | 4 | Feb 16, 2024 | |
| INCY Incyte | Maintains: Buy | $82 → $81 | $52.05 | +55.62% | 2 | Feb 14, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $182 | $138.44 | +31.46% | 9 | Feb 8, 2024 | |
| EXEL Exelixis | Initiates: Buy | $31 | $23.46 | +32.14% | 1 | Dec 15, 2023 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $36 → $60 | $41.26 | +45.42% | 8 | Jul 31, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $103 → $96 | $80.76 | +18.87% | 3 | Jun 30, 2023 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $55 → $50 | $11.82 | +323.01% | 3 | Mar 13, 2023 | |
| NTLA Intellia Therapeutics | Upgrades: Neutral | $48 → $39 | $21.40 | +82.24% | 2 | Jan 24, 2023 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $38 → $34 | $25.11 | +35.40% | 2 | Nov 10, 2022 | |
| PTCT PTC Therapeutics | Initiates: Buy | $70 | $32.15 | +117.73% | 1 | Sep 1, 2022 | |
| IMRX Immuneering | Maintains: Equal-Weight | $18 → $12 | $1.42 | +745.07% | 2 | Jul 15, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $170 → $164 | $143.95 | +13.93% | 6 | Jul 15, 2022 | |
| ARQT Arcutis Biotherapeutics | Maintains: Overweight | $36 → $39 | $8.32 | +368.75% | 6 | Jun 7, 2022 | |
| SNDX Syndax Pharmaceuticals | Maintains: Equal-Weight | n/a | $21.13 | - | 1 | Oct 12, 2021 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | n/a | $1.03 | - | 1 | Oct 12, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $7.75 | - | 2 | Oct 12, 2021 | |
| AVRO AVROBIO | Maintains: Overweight | n/a | $1.19 | - | 2 | Oct 12, 2021 |
Madrigal Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $204.02
Upside: +87.24%
Schrödinger
Mar 1, 2024
Maintains: Buy
Price Target: $47 → $39
Current: $24.38
Upside: +59.97%
Cogent Biosciences
Feb 26, 2024
Maintains: Buy
Price Target: $11 → $13
Current: $6.50
Upside: +100.00%
BridgeBio Pharma
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $25.62
Upside: +79.55%
Blueprint Medicines
Feb 16, 2024
Maintains: Sell
Price Target: $54 → $65
Current: $91.34
Upside: -28.84%
Incyte
Feb 14, 2024
Maintains: Buy
Price Target: $82 → $81
Current: $52.05
Upside: +55.62%
Ascendis Pharma
Feb 8, 2024
Maintains: Buy
Price Target: $146 → $182
Current: $138.44
Upside: +31.46%
Exelixis
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $23.46
Upside: +32.14%
Ionis Pharmaceuticals
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $41.26
Upside: +45.42%
BioMarin Pharmaceutical
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $80.76
Upside: +18.87%
Pliant Therapeutics
Mar 13, 2023
Maintains: Buy
Price Target: $55 → $50
Current: $11.82
Upside: +323.01%
Intellia Therapeutics
Jan 24, 2023
Upgrades: Neutral
Price Target: $48 → $39
Current: $21.40
Upside: +82.24%
Mirum Pharmaceuticals
Nov 10, 2022
Maintains: Buy
Price Target: $38 → $34
Current: $25.11
Upside: +35.40%
PTC Therapeutics
Sep 1, 2022
Initiates: Buy
Price Target: $70
Current: $32.15
Upside: +117.73%
Immuneering
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.42
Upside: +745.07%
Alnylam Pharmaceuticals
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $143.95
Upside: +13.93%
Arcutis Biotherapeutics
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $8.32
Upside: +368.75%
Syndax Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $21.13
Upside: -
Karyopharm Therapeutics
Oct 12, 2021
Maintains: Overweight
Price Target: n/a
Current: $1.03
Upside: -
Ironwood Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $7.75
Upside: -
AVROBIO
Oct 12, 2021
Maintains: Overweight
Price Target: n/a
Current: $1.19
Upside: -